Introduction
Hepatitis B virus (HBV) infection is one of the major public-health problems in the world. More than 350 million people are chronic carriers of HBV [1] . Approximately, 15-40% of infected patients develop cirrhosis, liver failure, or hepatocellular carcinoma (HCC) [2] . Chronic HBV infection is characterized by persistence of HBV surface antigen (HBsAg) and viremia after acute infection [3, 4] . Early studies revealed that clearance of HBsAg in patients with HBV infection is associated with disappearance of viremia and remission of the disease. However, accumulated data showed that a low level of HBV DNA remains detectable in serum or liver tissue in some patients without HBsAg in the serum [5] . This clinical entity has been termed 'occult HBV infection', which is defined as the presence of HBV DNA in the serum or liver without HBsAg in the serum. Occult HBV infection was reported for the first time as a source of HBV transmission in a case of blood transfusion by a donor positive for antibodies to hepatitis B core antigen (anti-HBc), which was the only marker of HBV infection [6] , and it is now a globally present entity. A single multinational investigation recorded the prevalence of occult hepatitis B in liver tissue to be 11% in Italy, 6 .9% in Hong Kong, and 0% in the UK [7] . When data from individual studies are considered, there seems to be a high prevalence in Asia [8] . A high prevalence of occult HBV infection was also demonstrated in patients with chronic hepatitis C virus (HCV) infection [5, [8] [9] [10] [11] , because of similar transmission modes between HBV and HCV.
According to recent reports, the HBV gene was detected in 37-85% of HCC patients negative for HBsAg, with or without HCV infection [12] [13] [14] [15] [16] [17] . We studied the HBV gene in liver tissue several years before the emergence of HCC, and in a retrospective study, we have already reported that the presence of HBV DNA in patients with HCV-related chronic liver disease appears to promote hepatocarcinogenesis [18] . In contrast, some published reports indicate a low prevalence of HBV DNA in patients with HCC without HBsAg [19] [20] [21] . Thus, the influence of occult HBV infection on hepatocarcinogenesis remains controversial. Moreover, most findings come from cross-sectional studies of patients with HCC. Until date, in Japan there has been no follow-up study evaluating the emergence of HCC over time in HBsAg-negative HCV-related chronic liver disease patients with or without occult HBV infection, using liver tissue. Therefore, using liver tissue, we performed a prospective study in patients with chronic HCV-related liver disease to elucidate whether occult HBV infection can promote the development of HCC in Japan. Furthermore, we evaluated the difference in the incidence rate of HCC and the incidence rate ratio among HBV DNA-negative patients and patients with high and low amounts of HBV.
Materials and Methods
Patients 167 patients with chronic HCV-related liver disease without serum HBsAg were studied. They underwent liver biopsy by laparoscopy at Okayama University Hospital, Okayama, Japan, between January 1997 and December 2003. Histological evaluation was performed using the METAVIR scoring system [22, 23] . All 167 patients were positive for both anti-HCV antibody and HCV RNA, and were negative for HBsAg in serum. Before liver biopsy, 14 patients had received interferon therapy but none was a longterm responder to the therapy. After liver biopsy, 123 patients were treated with interferon. Of them, 48 were treated with interferon-␣ after receiving interferon-␤ , 26 patients with interferon-␣ , 6 patients with interferon-␤ , 27 patients with interferon-␣ combined with ribavirin, 8 patients with pegylated interferon, and 8 patients with pegylated interferon combined with ribavirin. The response to interferon therapy was classified into two groups according to the serum HCV RNA status despite the serum alanine aminotransferase (ALT) level. Patients whose serum HCV RNA was undetectable by a qualitative assay during 6 months after cessation of interferon therapy were considered to have a sustained virological response (SVR). Non-SVR patients were defined as patients without clearance of HCV RNA from their serum 6 months after interferon therapy. Alcohol drinkers were defined as patients with average ethanol consumption of 1 30 g/day.
Informed consent to participation in the study was obtained from each patient, and the study was designed in accordance with the Declaration of Helsinki [24] .
Serological Studies
The serum samples were obtained at the time of liver biopsy, and were tested for serological markers of HCV and HBV. Anti-HCV antibody was detected by a second-generation enzyme immunoassay (EIA) (Kokusaishiyaku, Kobe, Japan). HCV RNA level was determined using reverse transcription-polymerase chain reaction (PCR) assay (Amolicor HCV test; Roche Diagnostics, Basel, Switzerland). HCV genotype was determined by site-specific PCR. Detection of HBsAg, antibody to hepatitis B surface antigen (antiHBs), and antibody to hepatitis B core antigen (anti-HBc) was done using EIA kits (Kokusaishiyaku). The average ALT level was calculated from each patient's ALT data during the follow-up period.
DNA Extraction and Detection of HBV DNA
We tried to detect HBV DNA in 167 liver biopsy tissues, using 2-mm long tissue samples, either frozen or dispersed in guanidium thiocyanate. Liver tissue dispersed in guanidium thiocyanate was centrifuged (12,000 rpm; 0.5 min), and the precipitate was used for DNA extraction. Liver tissue DNA was extracted with a QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Extracted DNA was analyzed for the presence of HBV DNA by performing both single and nested PCR. Initially, for the single PCR, HBV DNA in the following three regions was amplified by real-time PCR using LightCycler DX400 (Roche Diagnostics): the HBV S region (430-619, 190 bp), the HBV X region (1551-1625, 75 bp), and the HBV C region (2362-2479, 118 bp) ( table 1 ). In brief, amplification was performed to a final volume of 20 l reaction mixture containing 2 l of extracted DNA, 2 m M MgCl 2 , 1 M each of sense and anti-sense primers, 0.2 M fluorescent probe labeled with carboxyfluorescein (FAM) (Qiagen) and 2 l of LightCycler Fast Start DNA Master Hybridization Probe (Roche Diagnostics), containing Taq DNA polymerase, reaction buffer and a dNTP mix. Cycling conditions were as follows: after initial denaturation at 95° for 10 min, amplification was performed with 50 cycles of denaturation at 95° for 10 s, and annealing and extension at 60° for 25 s. Next, the nested PCR was performed to detect low volumes of HBV DNA. For the first PCR, HBV DNA was amplified from the following three regions: HBV S (414-989, 576 bp), HBV X (1421-1761, 341 bp) and HBV C (2190-2654, 465 bp) ( table 1 ). These primers for the first PCR of a nested PCR have been described recently [25] . Briefly, 100 l of reaction mixture contained 10 l of extracted DNA, 1.5 m M MgCl 2 , 0.2 m M dNTP mix, 2.5 U Taq polymerase (Roche Molecu-lar Systems, Branchburg, N.J., USA), and 0.5 M of each of sense and anti-sense primers. After denaturation at 95° for 5 min, amplification was performed with 35 cycles of denaturation at 94° for 1 min, annealing at 55° for 1 min, and extension at 72° for 1 min. For the second PCR, 2 l of the first PCR product was used, and HBV DNA was amplified by real-time PCR using LightCycler. The reaction mixture conditions and cycling protocol were same as those of the single PCR. ␤ 2 -Microglobulin was used as the eligibility marker of sample DNA, and a plasmid with tandemly inserted HBV DNA (VG041; provided by the Japanese Cancer Research Resources Bank, Tokyo, Japan) [26] was used as a positive control. Appropriate negative controls were also included in each PCR. The limits of sensitivity of the single PCR and the nested PCR were 200 and 30 copies/ml of HBV-DNA, respectively, as determined by testing a series of dilutions of plasmid of known concentration containing the HBV genome.
Follow-Up of the Patients
Follow-up began at the time of liver biopsy. After liver biopsy, to assess the presence or absence of HCC, all patients received regular clinical assessments and biochemical tests at least monthly, and had ultrasonography or computed tomography (CT) of the liver at least once every 6 months during the follow-up period. The final follow-up was defined as the date of diagnosis of HCC, the date of death, the date of moving to a location where follow-up was impossible, and the date of closing this study (May 31, 2006) .
Statistical Analysis
Student's t test, analysis of variance (ANOVA), Mann-Whitney U-test and the Kruskal-Wallis test were used to compare continuous variables, and 2 test was used for comparison between categorical variables. Continuous variables are expressed as mean 8 SD. The Kaplan-Meier method was used to calculate the cumulative incidence of HCC. The Wilcoxon test was used to compare time-to-event curves, because this test places more emphasis on earlier differences between curves. Independent factors related to hepatocarcinogenesis were evaluated in a Cox proportional hazards model. In this model, we performed univariate and multivariate analyses. Analyses were done using StatView version 5.0 (SAS Institute, Inc., Cary, N.C., USA) and JMP version 5.0 (SAS Institute, Inc.). A p value ! 0.05 was considered statistically significant. Table 2 shows the clinical characteristics of patients at the time of enrolment. All the 167 patients were classified into three groups: patients with high HBV copy number; patients with low HBV copy number, and patients who were HBV DNA-negative based on the results of HBV (29) 1 (17) 3 (23) 34 ( 
Results

Characteristics of Patients at Entry
Incidence of HCC in Patients with HCV-Related Chronic Liver Disease
At the beginning of this study, no patient had HCC on ultrasonography and CT. HCC developed in 12 of 167 patients (7.2%) during a mean follow-up at 42.5 8 24.3 months. Ten of 142 HBV DNA-negative patients (7.0%) developed HCC, whereas 2 of 25 HBV DNA-positive patients (8.0%) developed HCC. Among the 9 patients with a high HBV copy number, 2 (22.2%) developed HCC. In contrast, none of the 16 patients with a low amount of HBV developed HCC ( fig. 1 ). The total HCC incidence rate was 8% after 5 years and 24% after 7 years. Thus, the incidence rate of HCC increased as the observation period increased according to the KaplanMeier method. Figure 2 shows the cumulative incidence rate of HCC stratified by HBV DNA status in liver tissue. The incidence rate of HCC in HBV DNA-positive patients, including those with high and low HBV copy numbers, was not significantly different from the incidence rate in HBV DNAnegative patients ( fig. 2 a) (p = 0.59, Wilcoxon test). Of note, the incidence rate of HCC in patients with a high HBV copy number was significantly higher than that in patients with a low HBV copy number and HBV DNA-negative patients ( fig. 2 b) (p = 0.0172). The 5-year HCC incidence in patients with high HBV copy number was 31%, whereas that in patients with a low HBV copy number and HBV DNA-negative patients was 7% each, respectively.
We also calculated the cumulative incidence rate of HCC stratified by gender, history of blood transfusion, history of ethanol consumption, HCV genotype, average ALT level, interferon response, histological activity, stage of fibrosis, anti-HBs status, and anti-HBc status. Patients were divided into categories according to average ALT level ( ^ 80 IU/l, 1 80 IU/l), histological activity (low activity = A0, A1; high activity = A2, A3) and stage of fibrosis (early = F0, F1, F2; late = F3, F4). The incidence of HCC in patients with high histological activity was significantly higher than that of patients with low activity (p = 0.0094). A late stage of liver fibrosis was significantly associated with higher HCC incidence than an early stage (p ! 0.001). We observed no significant differences among other factors (data not shown).
Univariate and Multivariate Analyses of Risk Factors for HCC
To investigate the effect of each risk factor on the hepatocarcinogenesis, univariate and multivariate analyses were performed using a Cox proportional hazards model. Factors included in the univariate analysis were gender, ethanol consumption, HCV genotype, histological activity, stage of fibrosis, the effect of interferon, and HBV DNA status (high versus low HBV copy numbers and HBV-negative). The multivariate analysis included gender, ethanol consumption, histological activity, stage of Cumulative incidence of hepatocellular carcinoma according to HBV DNA status in liver tissue among HBsAg-negative patients with HCV-related chronic liver disease. a Cumulative incidence of HCC among patients with high or low HBV copy numbers and patients without HBV DNA. b Cumulative incidence of HCC among patients with a high HBV copy number and patients with a low HBV copy number or without HBV DNA.
fibrosis and HBV DNA status (high versus low HBV copy numbers and HBV-negative) ( table 3 ) .
In univariate analyses, for patients with high histological activity and a late stage of fibrosis the incidence rate ratio was 2.37 (95% CI 1.21-6.06, p ! 0.01) and 5.40 (95% CI 2.38-23.1, p ! 0.01), respectively. Thus, both high histological activity and a late stage of fibrosis conferred a significantly high risk of HCC according to this univariate analysis. For patients with a high HBV copy number the incidence rate ratio was 1.91 (95% CI 0.75-3.73, p = 0.15). Gender, alcohol, HCV genotype, interferon effect and HBV DNA status were not associated with risk of HCC in the univariate analysis ( table 3 a) .
By multivariate analysis, high histological activity and a late stage of fibrosis had an incidence rate ratio of 1.15 (95% CI 0.34-5.67, p = 0.83) and 3.45 (95% CI 1.19-16.7, p = 0.02). The incidence rate ratio for a high HBV copy number was 1.49 (95% CI 0.50-4.31, p = 0.45). Only a late stage of fibrosis was a strong risk factor for HCC according to the multivariate analysis ( table 3 b). Table 4 shows features of 25 occult HBV-positive patients with high and low copy numbers of HBV, including regions of HBV shown by nested PCR, HBV DNA level in liver tissue, HCV genotype, average ALT level, IFN response, stage of fibrosis, anti-HBs status, anti-HBc status, and the occurrence of HCC. HBV DNA could be quantified only in liver tissue of patients with a high HBV copy number.
Features of Occult HBV-Positive Patients with High and Low HBV Copy Numbers
All patients with a high amount of HBV had at least two positive regions in the nested PCR. Patients with a high amount of HBV had more positive regions than patients with a low amount of HBV. Two HCC patients were positive for all three regions (S, X and C). The level of HBV DNA in liver tissue among 9 patients with a high HBV copy number ranged from 43 to 1,530 copies/ g of total liver DNA. The level of HBV DNA in 2 HCC patients was 227 and 50 copies/ g of total liver DNA, respectively. HCV genotype was 1b in both of 2 HCC patients. The mean ALT level was 67 8 40 IU/l in patients with a high HBV copy number and 39 8 26 IU/l in those with a low HBV copy number (difference not significant). The mean ALT levels of HCC patients Nos. 2 and 8 were 120 and 75 IU/l, respectively. Among 8 patients with a high HBV copy number treated with IFN, IFN responses of 5 patients were Non-SVR, 1 was SVR, and 2 had no data. Both of 2 HCC patients were Non-SVR. Of 13 patients with a low HBV copy number treated with IFN, 7 were Non-SVR, 5 were SVR, and 1 had no data. Stages of fibrosis were F3 and F2 in 2 HCC patients with a high HBV copy number, whereas among 10 HCC patients without HBV DNA, 6 were F4, and 4 were F3 (data not shown). Of interest, serum anti-HBs and anti-HBc statuses did not correlate with HBV DNA in liver tissue. Of 6 patients with a high HBV copy number who were examined for antiHBs, only 1 was positive, and of 7 patients with a high HBV copy number examined for anti-HBc, the same one was positive. Among 13 patients with a low HBV copy number examined for anti-HBs, 3 were positive, and among 14 patients with a low HBV copy number examined for anti-HBc, 5 were positive. HCC patient No. 2 had both anti-HBs and anti-HBc, whereas HCC patient No. 8 had neither anti-HBs nor anti-HBc.
Discussion
We conducted a prospective assessment of patients with HCV-related chronic liver disease. We showed that HBsAg-negative patients with HCV-related chronic liver disease who had a high HBV copy number in liver tissue appear to have a higher risk of HCC than those without HBV DNA or with a low HBV copy number. However, confirmation that a high HBV copy number in liver tissue promotes hepatocarcinogenesis was not obtained from our univariate and multivariate analyses. The results of this study also indicate that a late stage of liver fibrosis is a strong risk factor for HCC, as indicated by a multivariate analysis using the Cox proportional hazards model, as many other reports have revealed [27] [28] [29] .
Two meta-analyses concluded that there is synergistic carcinogenic interaction between HBV and HCV [30, 31] . HBV is capable of initiating the neoplastic process, while HCV may act as a promoter, and the two viruses may cooperate in causing HCC [30] . On the other hand, the association between occult HBV infection and HCC devel- 2a  16  SVR  3  ---20  +  +  -1b  33  SVR  1  ND  ND  -21  +  +  -2a  10  SVR  1  ---22  -+  -1b  70  /  1  ---23  -+  +  1b  29  Non-SVR  2  +  +  -24  -+  -1b  28  Non-SVR  1  ND  ND  -25  --+  2b  24  SVR  2 opment is reinforced by many studies [10, [32] [33] [34] [35] [36] [37] . The capacity of occult HBV for transformation may be a consequence of the integration of viral DNA into the host's genome. Furthermore, the HBV X gene product is a potent transactivator of a number of signaling pathways that probably contribute to HCC [38] . Cases of HCC arising in the setting of occult hepatitis B show clonal integration of HBV DNA in many but not all cases [15, 16, 38, 39] , and frequently express the viral X gene [40] , which is often mutated [8, 34] . Thus, the integration of HBV DNA might play an important role in hepatocarcinogenesis in occult HBV-positive patients with HCV-related chronic liver disease. In this study, stage of liver fibrosis in HCC patients without HBV DNA was more advanced, compared with that in HCC patients with a high HBV copy number. This result suggests that occult HBV infection promotes the development of HCC in patients with HCVrelated chronic liver disease in the absence of severe fibrosis. In addition, our result raises the possibility that a high HBV copy number increases the likelihood that the virus integrates into the host's genome, consequently accelerating the development of HCC in patients with HCVrelated chronic liver disease. The facts that the presence of more positive HBV DNA regions in patients with a high HBV copy number than in patients with a low copy number, and the fact that 2 HCC patients had all three regions of HBV (S, X and C) might support this hypothesis. To confirm this hypothesis, it is necessary to find out whether HBV DNA persists as an integrated form or as a free episomal form. Furthermore, to evaluate the replication of HBV DNA in liver tissue, testing for the presence of covalently closed circular HBV DNA would be useful; however, we did not perform this test. In Japan, the prevalence of occult hepatitis B in patients infected with HCV ranged from 37 to 95% [41] [42] [43] [44] [45] [46] compared with 0 to 20% [45, [48] [49] [50] in patients in control populations. In our study, liver tissue from 25 (15.0%) of 167 patients infected with HCV was positive for HBV DNA, and these patients were considered to be occult HBV-positive patients. Because these percentage and number of occult HBV patients were slightly low, our univariate and multivariate analyses of occult HBV infection may not have shown a significant incident rate ratio for HCC. The sensitivity and specificity of the PCR in different studies have varied, and the kind of samples (serum or liver tissue) has differed from one study to another [11] . Consequently, there are discrepancies between the frequencies obtained from previous reports. Studies evaluating the presence of occult HBV in both liver and serum samples have shown that a significant percentage of subjects with negative HBV DNA in serum prove to be positive at the liver tissue level [47] [48] [49] [50] . Taking this recent evidence into account, there is no doubt that analysis of liver DNA extracts is the best way to detect occult HBV. The gold standard test for occult HBV is the analysis of DNA extracts from liver samples by a nested PCR technique [11] . Therefore, the sensitivity and specificity of our nested PCR does not account for the low prevalence of occult HBV infection in our study, because the sensitivity and specificity were high enough to detect occult HBV infection using liver tissue. On the other hand, it has been revealed that the prevalence of occult HBV infection is dependent on the interval from HBsAg clearance to assessment of HBV DNA. The longer the interval from HBsAg clearance, the lower the prevalence of occult HBV infection [5] . We could not estimate when HBsAg clearance occurred in each of our patients, but a longer interval from HBsAg clearance is one possible reason for the low prevalence of occult HBV infection in our study. In addition, some heterogeneity has been observed in the distribution of the viral genome within the liver [10] , and this heterogeneity is another possible reason.
In many instances, occult HBV infection is associated with anti-HBc with or without anti-HBs, and serum antiHBc and anti-HBs are considered markers of past HBV infection that may also serve as useful markers for HCC risk factors [51] [52] [53] . However, no anti-HBs or anti-HBc can be detected in a significant proportion of patients with occult B infection [54] . It has been reported that more than 20% of occult carriers are negative for all serum markers of HBV infection [8] . In individuals positive for anti-HBc as the only HBV marker, there may be three different situations: resolving acute HBV infection after HBsAg has disappeared, but with undetectable amounts of anti-HBs; a past HBV infection, especially an infection that occurred in the past, anti-HBs having fallen to an undetectable level, and a true occult HBV infection with a low level of HBV replication [3, 4, 6, 10, [55] [56] [57] . In the present study, anti-HBc and anti-HBs did not always correlate with HBV DNA in liver tissue. Furthermore, a significant difference was not observed between the cumulative HCC incidence in patients positive and negative for anti-HBc.
The results of our study must be interpreted with caution because of its limitations. First, our study population was small. Because liver biopsy is a more invasive method than taking serum from patients, it was difficult to get an adequate number of liver tissue samples. Therefore, we found only a small number of occult HBV-positive patients, and this would have affected our results. Second, the observation period was not long enough to reveal a substantial association between the presence of HBV DNA in liver tissue and hepatocarcinogenesis in patients with HCV-related chronic liver disease. With a longer observation period, the number of patients with HCC increases. Third, after liver biopsy, 123 of 167 patients were treated by interferon or interferon combined with ribavirin. Although there were no significant differences among a high HBV copy number group, a low HBV copy number group and a HBV DNA-negative group with respect to interferon response, these treatments may have directly affected hepatocarcinogenesis. More large-scale studies with larger populations and longer observation periods are needed for a definite conclusion.
In conclusion, this study indicates that the presence of a high amount of HBV DNA in liver tissue of HBsAgnegative patients with HCV-related liver disease was associated with the development of HCC. When HBsAgnegative patients with HCV-related liver disease have the opportunity for liver biopsy before interferon therapy, for example, the detection of a high HBV copy number in liver tissue could be used to identify patients who should be assessed more carefully to obtain an earlier diagnosis of HCC.
